Cancer antigen-specific CTL induction and immune cell therapy using cancer antigen peptide, T cell co-stimulation, and immunosuppressive cell regulation

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10137
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Shiga University of Medical Science
• Principal Investigator: Miyake Toru 滋賀医科大学, 医学部, 助教 (70581924)
• Co-Investigator(Kenkyū-buntansha): 北村 直美 滋賀医科大学, 医学部, 助教 (30572474) ; 谷 眞至 滋賀医科大学, 医学部, 教授 (60236677) ; 清水 智治 滋賀医科大学, 医学部, 准教授 (70402708) ; 目片 英治 滋賀医科大学, 医学部, 教授 (80314152) ; 村田 聡 滋賀医科大学, 医学部, 講師 (90239525)
• Research Collaborator: Pham Minh Ngoc , 大学院生 ; Kojima MASATSUGU , 助教
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 免疫細胞治療 / 養子免疫 / 抗体療法 / 補助刺激 / 免疫チェックポイント阻害

Outline of Final Research Achievements

The main problems of anti-tumor immune cell therapy are followings; there is a limitation of the number of tumor-specific CTLs that can be induced; CTLs transferred to tumor bearing host cannot proliferate in vivo, lose their function, and undergo apoptosis.
We studied to develop a method by which HER2-specific CTL transferred into the HER2-positive breast tumor-bearing mouse can proliferate in the tumor-bearing environment and maintain antitumor activity. As a result, we have demonstrated that tumor Ag-specific CTLs that were generated in vitro in the presence of an MHC-class I-restricted peptide and OX40 co-stimulation are early-differentiated effector T cells and also have the ability to eradicate tumors, and the potential for expansion and maintenance in tumor-bearing host.

Free Research Field

消化器外科